When wishful thinking leads to a misty-eyed appraisal: The story of the adjuvant colon cancer trials with edrecolomab

Journal of Clinical Oncology

Volumn 27, Issue 12, 2009, Pages 1926-1929

  Schmoll, Hans Joachim ^a   Arnold, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADECATUMUMAB; EDRECOLOMAB; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOSURVEILLANCE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; THERAPY EFFECT; TREATMENT RESPONSE; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; TREATMENT OUTCOME;

EID: 65349124782     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6284     Document Type: Editorial

References (14)

1. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl Med 352:476-487, 2005
2. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
3. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer trials (IMPACT) investigators. Lancet 345:939-944, 1995
4. Herlyn D, Wettendorff M, Schmoll E, et al: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci U S A 84:8055-8059, 1987
5. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma: German Cancer Aid 17-1A Study Group. Lancet 343:1177-1183, 1994
6. Riethmüller G, Holz E, Schlimok G, et al: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788-1794, 1998
7. Hartung G, Hofheinz RD, Dencausse Y, et al: Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: A multicenter randomized phase III study. Onkologie 28:347-350, 2005
8. Colacchio TA, Niedzwiecki D, Compton C, et al: Phase III trial of adjuvant immunotherapy with MOAb 17-1 following resection of stage II adenocarcinoma of the colon (CALGB 9581). J Clin Oncol 22:250s, 2004 (suppl; abstr 3522)
9. Punt CJ, Nagy A, Douillard YJ, et al: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Lancet 360:671-667, 2002
10. Fields A, Keller A, Schwartzberg L, et al: Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 27:1941-1947, 2009
11. Herlyn D, Steplewski Z, Herlyn M, et al: Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40:717-721, 1980
12. Ioannidis JP: Contradicted and initially stronger effects in highly cited clinical research. JAMA 294:218-228, 2005
13. Zelen M: A new design for randomized clinical trials. N Engl J Med 300:1242-1245, 1979
14. Micromet Key Events for 2009. http://www.bio-medicine.org/ medicinetechnoloy-1/Micromet-Key-Events-for-2009-3654-2/